Search This Blog

Tuesday, May 19, 2026

Relay initial Phase 2 data for zovegalisib in vascular anomalies 60% volumetric response rate

 

Relay Therapeutics reports initial Phase 2 ReInspire data for zovegalisib in PIK3CA-driven vascular anomalies with 60% volumetric response rate

  • Initial Phase 2 ReInspire data show favorable safety profile for zovegalisib in PIK3CA-driven vascular anomalies.
  • Relay Therapeutics opens adult and adolescent expansion cohorts in ReInspire Phase 2 trial at selected doses.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)